Latent TGF-β-binding Proteins Affect the Fibrotic Process in Renal Impairment and Cardiac Dysfunction

Recruiting

• Conditions: Acute Coronary Syndrome; Acute Coronary Syndrome With Renal Dysfunction

• Registration Number: NCT04998227
• Lead Sponsor: National Taiwan University Hospital

Brief Summary

The project is planed to explore the impact of LTBP4 and other matrix protein and potentially related biomarkers on renal outcomes, cardiac outcomes and all-cause mortality in patients with suspected acute coronary syndrome (ACS).

Detailed Description

The investigators will collect the blood samples from patients with suspect ACS. LTBP4 will be the first matrix protein that are going to understand. Upon hospital arrival, blood samples around 8 ml will be collected and the 2nd collection will be two weeks to one month after the event. The third collection will be one year later. In the between, if any ACS event develop, blood samples will be collected as protocols.

Study Timeline

• Study Start: 2021-04-26
• Study First Submitted: 2021-08-03
• Study First Submitted QC: 2021-08-03
• Study First Posted: 2021-08-10
• Status Verified: 2024-04
• Last Update Submitted: 2024-04-15
• Last Update Posted: 2024-04-17
• Primary Completion: 2025-03-01
• Study Completion: 2025-03-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 300

Inclusion Criteria

• acute coronary syndrome patients

Read More

Exclusion Criteria

• cardiogenic shock, pregnancy, end-stage renal disease

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Change of renal functions	One month, Six month and one year	The investigators will follow up Cr and eGFR levels correlate with LTBP4 levels
Incidence of required myocardial revascularization	3 years
All cause mortality	3 years
Incidence of hospitalization	3 years

Trial Locations

Locations (1)

National Taiwan University Hospital; 🇨🇳 Taipei, Taiwan